1,5-Dicaffeoylquinic acid structure
|
Common Name | 1,5-Dicaffeoylquinic acid | ||
---|---|---|---|---|
CAS Number | 30964-13-7 | Molecular Weight | 516.451 | |
Density | 1.6±0.1 g/cm3 | Boiling Point | 819.9±65.0 °C at 760 mmHg | |
Molecular Formula | C25H24O12 | Melting Point | 225-227 °C | |
MSDS | Chinese USA | Flash Point | 278.1±27.8 °C |
Use of 1,5-Dicaffeoylquinic acidCynarin is an antichoke agent with a variety of biological activities including antioxidant, antihistamic and antiviral activities. |
Name | 1,3-dicaffeoylquinic acid |
---|---|
Synonym | More Synonyms |
Description | Cynarin is an antichoke agent with a variety of biological activities including antioxidant, antihistamic and antiviral activities. |
---|---|
Related Catalog | |
In Vitro | Cynarin inhibits taste receptors, making water to be sweet. It has been shown to have some pharmacological properties including hypocholesterolemic, hepatoprotective, antiviral, antibacterial, and antihistamic effects. Cynarin has marked antioxidant, anticholinergic, reducing ability, radical-scavenging, and metal-binding activities. Cynarin demonstrates 87.72% inhibition of linoleic acid lipid peroxidation at 30 mg/mL concentration. Cynarin exhibits effective DMPD+, ABTS+/sup>, O2-, DPPH1, and H2O2 scavenging effects, reducing capabilities and Fe2+ chelating effects. IC50 and Ki of cynarin for acetylcholinesterase enzyme inhibition are 243.67nM and 39.34±13.88 nM, respectively[1]. Cynarin is a potential immunosuppressant that blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. Cynarin blocks about 87% of the CD28-dependent "signal 2" pathway of T-cell activation under the condition of one to one ratio of T-cell and B-cell. Cynarin binds to the "G-pocket" of CD28 and thus interrupts the site of interaction between CD28 and CD80[2]. |
Cell Assay | The cytotoxicity of cynarin treatment of T-cells is measured by MTT colorimetric assay. 100 μL Jurkat cells are incubated with cynarin (0-1000 μg/mL) for 24 h at 37°C. The cell solution is then centrifuged and the supernatant removed. 200 μL of MTT is added and the cell solution is incubated again for 4 h at 37°C. 200 μL of DMSO lysis buffer is added into the cell medium and the concentration of dissolved MTT crystals is measured by plate reader at 560 nm[2]. |
References |
Density | 1.6±0.1 g/cm3 |
---|---|
Boiling Point | 819.9±65.0 °C at 760 mmHg |
Melting Point | 225-227 °C |
Molecular Formula | C25H24O12 |
Molecular Weight | 516.451 |
Flash Point | 278.1±27.8 °C |
Exact Mass | 516.126770 |
PSA | 211.28000 |
LogP | 1.64 |
Vapour Pressure | 0.0±3.1 mmHg at 25°C |
Index of Refraction | 1.719 |
Storage condition | 2-8°C |
RIDADR | NONH for all modes of transport |
---|---|
HS Code | 2932999099 |
HS Code | 2932999099 |
---|---|
Summary | 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Chem. Res. Toxicol. 23 , 171-83, (2010) Drug-induced liver injury is one of the main causes of drug attrition. The ability to predict the liver effects of drug candidates from their chemical structures is critical to help guide experimental... |
|
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
J. Med. Chem. 51 , 6740-51, (2008) The work provides a new model for the prediction of the MAO-A and -B inhibitor activity by the use of combined complex networks and QSAR methodologies. On the basis of the obtained model, we prepared ... |
|
Natural product inhibitors of protein-protein interactions mediated by Src-family SH2 domains.
Bioorg. Med. Chem. Lett. 19 , 3305-9, (2009) In this Letter, we report the natural products salvianolic acid A, salvianolic acid B, and caftaric acid as inhibitors of the protein-protein interactions mediated by the SH2 domains of the Src-family... |
Listrocol |
Acido,1,4-dicaffeilchinico |
(1R,3R,4S,5R)-1,3-Bis{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid |
[1R-(1a,3a,4a,5b)]-1,3-Bis[[3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl]oxy]-4,5-dihydroxycyclohexanecarboxylic Acid |
1,5-Dicaffeoylquinic acid |
1,3-DICAFFEOYLQUINIC ACID |
1,3-O-Dicaffeoylquinic acid |
(1R,3R,4S,5R)-1,3-Bis{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-4,5-dihydroxycyclohexanecarboxylic acid |
1-Carboxy-4,5-dihydroxy-1,3-cyclohexylenebis-(3,4-dihydroxycinnamate) |
3,4-Dihydroxycinnamic Acid 1-Carboxy-4,5-dihydroxy-1,3-cyclohexylene Ester |
CINARINE |
1,4-Dicaffeylquinic acid |
MFCD00075714 |
Caffeic Acid 1-Carboxy-4,5-dihydroxy-1,3-cyclohexylene Ester |
Cinarcaf |
Cyclohexanecarboxylic acid, 1,3-bis[[(2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-4,5-dihydroxy-, (1R,3R,4S,5R)- |
1,5-Dicaffeylquinic Acid |
Cynarine |
Cynara scolymus L, |
Quinic Acid 1,5-Dicaffeic Ester |
Plemocil |
Cynarin |
CINARAN |
EINECS 214-655-7 |
Dicaffeoylquinic Acid, 1,3- |